Published on in Vol 5 , No 2 (2017) :February
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
1 AbbVie Inc., North Chicago, IL, US
2 AiCure, LLC, New York, NY, US
3 CNS Network, LLC, Garden Grove, CA, US
4 Chuang-Stein Consulting, Kalamazoo, MI, US
5 EarlyPhase Sciences, Inc., Cary, NC, US
*all authors contributed equally